Coya Therapeutics Inc. (COYA:NASDAQ) has now reached the 100th participant enrolled in its Phase 2/3 ALSTARS trial of COYA 302 for amyotrophic lateral sclerosis (ALS). The 100th participant was enrolled. This milestone moves the company closer to completing the planned 120-participant target.
Full enrollment is projected within weeks, positioning the firm for topline data readout in early Q2 2027. The randomized, multicenter, double-blind, placebo-controlled study tests two dosing regimens of COYA 302 against placebo.
Why the Enrollment Progress Matters for Investors Now
Reaching 100 participants signals steady recruitment momentum in a disease area with high unmet need. ALS is a progressive neurodegenerative condition that affects motor neurons controlling voluntary muscles used for speaking, swallowing, and breathing. Positive results could support further development steps and strengthen the company's position.
The trial includes a 24-week double-blind treatment phase followed by a 24-week blinded active-treatment extension, allowing up to 48 weeks of data collection. The primary endpoint tracks the change in disease severity from baseline to Week 24 using the ALSFRS-R score versus placebo. Secondary measures cover safety, tolerability, biological activity, and biomarker levels.
Key Investor Takeaways
- Coya has enrolled 100 of 120 planned participants in the Phase 2/3 ALSTARS trial, with completion expected shortly and topline data targeted for early Q2 2027.
- COYA 302 combines low-dose interleukin-2 and CTLA-4 immunoglobulin and holds an FDA Fast Track designation in ALS.
- Additional data from ALS and Alzheimer's programs are anticipated in the second half of 2026.
- Analysts from H.C. Wainwright, Roth, and Lake Street maintain Buy ratings with price targets of US$18, US$12, and US$17, respectively.
- The company is Houston-based and focuses on regulatory T cell therapies to address inflammation.
- Market cap stands at approximately US$111.66 million with 23.46 million shares outstanding.
Company Position and Pipeline Assets
Coya Therapeutics develops treatments that modulate regulatory T cells to reduce systemic and neuroinflammation. COYA 302 represents the lead candidate currently in the ALSTARS trial. The company also plans to release single-cell proteomics data from earlier ALS and Alzheimer's studies in the second half of 2026, along with the potential publication of COYA 303 in vivo data.
A successful ALSTARS outcome could support a potential Biologics License Application filing pathway and possible commercialization steps in 2028.
Broader Sector Timing and Funding Environment
The U.S. government provided US$90 million in federal funding for ALS research. Global medicine use trends point to growth in innovative therapeutics through 2030, particularly in areas such as oncology and immunology. IQVIA discussed the global pharma market projection for 2026.
Pharma funding patterns showed mixed results between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. Global biotech deals reached US$228.4 billion in 2025. J. Edward Moreno of Sherwood News reported R&D spending among top pharmaceutical companies declined 3.6 percent in 2025. BCG talked about trends biopharma companies need to be aware of in 2026 at the start of the year.
Views and Valuation Context
Analysts continue to highlight the upcoming data readouts. Raghuram Selvaraju of H.C. Wainwright reiterated a Buy rating and US$18 price target, noting that positive ALSTARS data could support pivotal development in ALS late in 2027.
Roth analyst Boobalan Pachaiyappan maintained a Buy rating and US$12 target, citing the potential for a 2.5-point ALSFRS-R improvement to support a BLA filing.
Lake Street's Chad Messer reiterated a Buy rating and US$17 target, emphasizing that full enrollment, Phase 2/3 status, and Fast Track designation strengthen the investment case.
Newsletter writer Chen Lin observed steady enrollment of four to five patients per week and noted the competitive landscape after a competitor halted an ALS program.
Streetwise Ownership Overview*
Coya Therapeutics Inc. (COYA:NASDAQ)
Share Structure and Near-Term Events1
Coya Therapeutics Inc. has a market cap of US$111.66 million and 23.46 million shares outstanding. The 52-week range is US$3.71 to US$7.75.
Institutions hold 33.23 percent, strategic investors hold 13.69 percent, management and insiders hold 1 percent, and retail investors hold the remaining 52.08 percent.
Common Questions from Investors
Q: What is the primary endpoint in the ALSTARS trial?
A: The primary endpoint measures change in ALS disease severity from baseline through Week 24 using the ALSFRS-R total score compared with placebo.
Q: What does the Fast Track designation provide?
A: FDA Fast Track designation for COYA 302 in ALS is intended to facilitate development and expedite review of drugs addressing serious conditions with unmet medical needs.
Q: When is topline data expected?
A: Topline data from the ALSTARS trial is targeted for early Q2 2027 following completion of the 120-participant enrollment.
Q: What are the next data catalysts after enrollment?
A: Additional single-cell proteomics data from ALS and Alzheimer's studies, plus a potential COYA 303 publication, are planned for the second half of 2026.
Investors should weigh clinical, regulatory, and financing risks typical of development-stage biotechnology companies when evaluating the stock.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
